Human papillomavirus DNA in plasma of patients with cervical cancer

Pornthanakasem, Wichai; Shotelersuk, Kanjana; Termrungruanglert, Wichai; Voravud, Narin; Niruthisard, Somchai; Mutirangura, Apiwat

doi:10.1186/1471-2407-1-2

Cited by 104 publications

(130 citation statements)

References 21 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Not surprisingly, soon after this initial breakthrough essentially all other types of tumorspecific DNA changes were discovered in cfDNA, such as changes in the status of microsatellite markers including loss of heterozygosity (LOH; refs. 8, 9); gene amplifications (10,11); the presence of the oncogenic viral DNA (12)(13)(14)(15); and hypermethylation of the promoter regions of tumor suppressor genes (16)(17)(18). While these early observations highlighted many possibilities for using ctDNA as a noninvasive approach to analyze tumor genomes, sufficiently sensitive and specific laboratory techniques to fully leverage this potential were not yet developed.…”

mentioning

confidence: 99%

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies

Volik¹,

Alcaide

Morin

et al. 2016

Molecular Cancer Research

300

235

View full text Add to dashboard Cite

Precision oncology is predicated upon the ability to detect specific actionable genomic alterations and to monitor their adaptive evolution during treatment to counter resistance. Because of spatial and temporal heterogeneity and comorbidities associated with obtaining tumor tissues, especially in the case of metastatic disease, traditional methods for tumor sampling are impractical for this application. Known to be present in the blood of cancer patients for decades, cell-free DNA (cfDNA) is beginning to inform on tumor genetics, tumor burden, and mechanisms of progression and drug resistance. This substrate is amenable for inexpensive noninvasive testing and thus presents a viable approach to serial sampling for screening and monitoring tumor progression. The fragmentation, low yield, and variable admixture of normal DNA present formidable technical challenges for realization of this potential. This review summarizes the history of cfDNA discovery, its biological properties, and explores emerging technologies for clinically relevant sequence-based analysis of cfDNA in cancer patients. Molecular barcoding (or Unique Molecular Identifier, UMI)-based methods currently appear to offer an optimal balance between sensitivity, flexibility, and cost and constitute a promising approach for clinically relevant assays for near real-time monitoring of treatment-induced mutational adaptations to guide evidence-based precision oncology.

show abstract

mentioning

confidence: 99%

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies

Volik¹,

Alcaide

Morin

et al. 2016

Molecular Cancer Research

300

235

View full text Add to dashboard Cite

show abstract

“…Real time methylation specific polymerase chain reaction (RT-MSP-PCR) allows quantitative estimates of promoter hypermethylated circulating DNA. Finally, particular viral sequences has been reported in circulation in patients suffering from some Epstein-Barr virus (EBV) associated cancers (nasopharyngeal carcinoma, EBV-associated Hodgkin's disease) as has circulating human papilloma virus (HPV) DNA sequences in plasma of cervical cancer patients associated with metastasis (43).…”

Section: Circulating Dna and Rna In Cancer Testingmentioning

confidence: 99%

Circulating nucleic acids in blood as biomarkers

Øvstebø¹,

Kierulf²,

Haug³

2009

Nor J Epidemiol

View full text Add to dashboard Cite

This short review on a rapidly expanding domain in biomarkers focuses on the value of markers derived from either circulating intracellular DNA and RNA (leukocytes) or from free DNA and RNA in plasma or serum. In circulating intracellular DNA biomarkers, importance has been pointed to reside in the ever increasing number of SNPs directly related to disease such as hemochromatosis or associated with genetic make up that leads to different drug-susceptibility. Quantitative gene expression profiling, increasingly using global expression platforms, is gaining momentum in various disease states such as cancer, inflammation, cardiovascular disease and diabetes. Circulating free nucleic acids in plasma or serum gain in importance as biomarkers particularly in cancer and foeto-maternal understanding. The surprising recent findings of circulating free mRNA carries the potential of examining normal and diseased plasma for global gene expression profiling -opening avenues to new biomarkers. When appropriate, this review gives reference to methodological considerations and refers the readers to important literature in the fields. SAMMENDRAGI denne korte oversiktsartikkelen redegjøres det for et biomarkørfelt som utvikler seg hurtig. Gjennom en blodprøve kan man få kjennskap til forandringer i sirkulerende leucocytter, intracellulaere nukleinsyrer (DNA og RNA) og fritt DNA og RNA fra plasma eller serum. Single Nucleotide Polymorphisms (SNPs) i DNA har allerede bekreftet sine muligheter som biomarkører (f.eks. Hemokromatose, Faktor V Leiden, Cytochrom P450 (CYP'er)). Stadig flere SNP'er vinner innpass i klinisk sammenheng. Siden sirkulerende hvite blodlegemer kan sies kontinuerlig å overvåke kroppens organer og vev, og dette avspeiles i disse blodcellers genekspresjon (RNA), knyttes det i dag forventninger til sykdomsspesifikke genekspresjonsprofiler. Både ved visse kreftformer, betennelsestilstander og hjertekar-sykdom viser hvite blodlegemer mer eller mindre tydelig sykdomsspesifikke genekspresjonsprofiler. Denne type sykdomsspesifikke genekspresjonsmarkører vil bli økende viktig fremover. Ved slike markører vil man kunne ha nytte av kvantitativ måling av enkeltmarkører, og også globale genekspresjonsprofiler på mikroarray-plattformer. Sirkulerende fritt DNA og kanskje saerlig RNA i plasma åpner for nye sykdomsmarkører i første rekke ved forskjellige kreftformer og ved foeto-maternelle problemstillinger. Oversikten gir også en henvisning til metodologiske referanser i disse feltene.

show abstract

“…En pacientes enfermos con cáncer la concentración de ADN libre disminuye en respuesta a quimioterapia (10) y se incrementa cuando hay una diseminación del tumor o metástasis (10)(11)(12)(13).…”

Section: Introductionunclassified

Cuantificación de ADN libre en plasma sanguíneo de voluntarios sanos en una población bogotana

Salazar-Jordan¹

2009

nova

View full text Add to dashboard Cite

ResumenEl ADN libre en sangre incrementa con algunas condiciones patológicas y ciertos estados fisiológicos. Varios reportes en la literatura han resaltado que el ADN libre en plasma o suero tiene potencial clínico como una posible herramienta para el pronóstico de cáncer en humanos. Sin embargo, hasta el momento no se tienen valores de referencia de individuos sanos con un tamaño de muestra representativo y tampoco se han descrito valores para poblaciones específicas como la bogotana. Es por ello que en el presente estudio se cuantificó la concentración de ADN libre en personas sanas de la población bogotana y así se estableció un rango normal o valor de referencia, adicionalmente se analizó la relación entre los niveles de ADN libre y las características como edad y género. La concentración de ADN libre en la población bogotana fue de 0,72 ng/µL y no se encontraron diferencias significativas entre las edades y los géneros.Palabras clave: ADN libre, ALU, PCR tiempo-real, rango de referencia.Abstract Quantification of free DNA in blood plasma of healthy volunteers in Bogotá population The free DNA in blood increases with some pathological conditions and certain physiological state. Several reports in the literature have highlighted that the free DNA in plasma or serum has clinical potential as a possible tool for the prognosis of human cancer. However, so far there are no reference values of healthy individuals with a representative sample size and no values have been reported for specific populations such as Bogota. That is why in this study we quantified the concentration of free DNA in healthy people of the Bogota population and thus established a normal range or reference value, the relationship between levels of free DNA and characteristics such as age and gender was further analyzed. The concentration of free DNA in the Bogota population was 0.72 ng/µL and no significant differences between ages and genders were found.

show abstract

Human papillomavirus DNA in plasma of patients with cervical cancer

Cited by 104 publications

References 21 publications

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies

Circulating nucleic acids in blood as biomarkers

Cuantificación de ADN libre en plasma sanguíneo de voluntarios sanos en una población bogotana

Contact Info

Product

Resources

About